€1bn charge by Eli Lilly in drug probe

ELI LILLY will record a $1.4 billion (€1.06bn) charge because of probes into past marketing of its top-selling Zyprexa schizophrenia drug and is in advanced talks to resolve the investigations, the company said on Tuesday.

Lilly will record the charge — $1.29 a share — in the third quarter.

The company has faced accusations it improperly marketed Zyprexa to patients who were not approved users and played down side effects such as weight gain.


Some days you’ve got to make your own sunshine, writes Annmarie O'ConnorTrend of the Week: Escape from lockdown loungewear with these creative closet options

Children’s author Sarah Webb didn’t want sixth class pupils to miss out on their graduation, so to mark their end of year she organised a series of inspirational videos delivered by well-known Irish people, says Helen O’CallaghanIrish celebrities help students say goodbye to primary school

We are all slowing our pace and appreciating the wonders around us, says Peter DowdallMagical maple holds us spellbound

Sustainable gardening tips and a fascinating documentary are among the offerings on your TV todayThursday TV Highlights: A Prime Time look at how schools will cope in the Covid era features in today's TV picks

More From The Irish Examiner